A patient walks into clinic weighing the same as they did a year ago. Their BMI is normal, sometimes even comfortably so. On paper, nothing looks alarming. Then a hand-grip test or a mid-arm muscle circumference measurement tells a different story: significant muscle loss, masked entirely by fluid retention or by fat mass that has quietly replaced lean tissue. This is sarcopenia in cirrhosis, and it is present in roughly a third to two-thirds of patients with advanced liver disease depending on the population studied and the method used to detect it — far more common than clinicians who rely on weight and BMI alone will ever suspect.

It matters because sarcopenia is not a cosmetic finding. It independently predicts mortality, predicts post-transplant complications, predicts longer ICU stays, and predicts a harder recovery from every decompensating event — ascites, hepatic encephalopathy, infection — that a cirrhotic liver will eventually produce. A patient who loses muscle loses physiological reserve, and reserve is exactly what determines who survives a septic episode or tolerates a transplant operation and who does not.

Why Cirrhosis Causes Muscle Loss

The liver in cirrhosis fails at several jobs that protect muscle. Glycogen storage capacity drops, so the body shifts to breaking down muscle protein for gluconeogenesis far earlier than it should — an overnight fast in a cirrhotic patient behaves metabolically like several days of starvation in someone with a healthy liver. Ammonia handling is impaired, and elevated ammonia directly interferes with muscle protein synthesis at the cellular level. Anorexia from early satiety — often driven by ascites compressing the stomach — reduces intake at precisely the moment demand is rising. Chronic low-grade inflammation adds a further catabolic push. The result is a patient who is losing muscle whether or not their weight on the scale suggests it.

Why It Gets Missed

BMI is the wrong tool here, and using it as a screening filter is the single biggest reason sarcopenia goes undiagnosed. Fluid retention — ascites, peripheral oedema — adds weight exactly as muscle is being lost, so a scale or a BMI calculation can show a stable or even rising number in a patient who is becoming progressively more sarcopenic underneath. A patient can be sarcopenic at any BMI, including overweight and obese — sarcopenic obesity is a recognised and particularly under-recognised phenotype in MASLD-related cirrhosis, where excess fat mass conceals substantial muscle depletion.

Screening: What Actually Works

Formal screening does not require expensive equipment. In routine practice:

Mid-arm muscle circumference or triceps skinfold — simple, bedside, reasonably validated in cirrhosis.
Hand-grip strength — fast, cheap, and correlates well with functional muscle mass and with clinical outcomes; a practical first-line screen in any liver clinic.
CT-based skeletal muscle index at the L3 vertebral level — the closest thing to a gold standard, and often already available from imaging done for other reasons (HCC surveillance, transplant work-up) — worth re-examining rather than ordering a fresh scan.
Bioelectrical impedance analysis — useful but its accuracy is reduced by ascites and fluid shifts, so interpret with caution in decompensated patients.

The practical point: any patient with cirrhosis being evaluated for transplant, or with two or more decompensating events, should have some form of objective muscle assessment — not a visual impression, and not BMI.

Protein Targets — and the Persistent Myth of Protein Restriction

The most damaging piece of outdated advice still circulating among patients and, occasionally, among clinicians is that protein should be restricted in liver disease to prevent hepatic encephalopathy. This is wrong, and has been wrong for years. Protein restriction accelerates sarcopenia without meaningfully reducing encephalopathy risk, and current recommendations are unambiguous: patients with cirrhosis need more protein than the general population, not less.

The working target is 1.2–1.5 g/kg body weight per day, higher again — up to 1.5–2.0 g/kg/day — in patients who are acutely unwell, malnourished, or peri-transplant. Even in a patient with a history of hepatic encephalopathy, the correct response to an episode is to identify and treat the precipitant — infection, GI bleed, constipation, a missed lactulose dose — not to cut protein.

Practical measures that make a real difference:

A late-evening snack containing 50–80 g of carbohydrate — shortens the overnight catabolic fasting window that cirrhotic metabolism handles so poorly.
Distributing protein across the day in smaller, frequent meals rather than one large dose — improves tolerance and utilisation.
Branched-chain amino acid (BCAA) supplementation — particularly useful where standard dietary protein alone is poorly tolerated, or in patients with more advanced disease.
Vegetable and dairy protein sources tend to be better tolerated than red meat in some patients and are a reasonable first adjustment if symptoms suggest intolerance — not a reason to reduce total protein intake.

Building It Back: Exercise and Rehabilitation

Nutrition alone does not reverse sarcopenia — resistance exercise is the other half of the equation, and it is safe in compensated and most decompensated cirrhosis when supervised appropriately. Even modest, structured resistance training improves muscle mass and functional capacity in cirrhotic patients, including those awaiting transplant. Deconditioning from inactivity — often driven by fatigue or a well-meaning but mistaken instinct to “rest” — compounds the metabolic drivers of muscle loss. Where feasible, referral for structured physiotherapy or a rehabilitation programme before transplant listing is worth building into routine care rather than treating as optional.

Why This Belongs in Every Pre-Transplant Work-Up

Sarcopenia assessment is not an academic add-on to transplant evaluation — it changes management. A sarcopenic patient with an otherwise borderline MELD score may benefit from a structured pre-habilitation window before listing. Post-transplant, baseline muscle mass predicts ICU length of stay, ventilator time, and infection risk. Patients and families are often focused entirely on the liver itself; explaining that muscle mass is being tracked as carefully as liver function tests tends to reframe nutrition and physical activity from an afterthought into something they take seriously.

The Bottom Line

Malnutrition and sarcopenia affect the majority of patients with advanced cirrhosis, are systematically under-detected because BMI and weight are the wrong screening tools, and are actively worsened by outdated protein-restriction advice that should have been retired years ago. The fix is not complicated: screen with grip strength or muscle circumference rather than BMI, target 1.2–1.5 g/kg/day protein (higher if malnourished or peri-transplant), add a late-evening carbohydrate snack, and build in resistance exercise wherever the patient’s condition allows. None of this requires advanced technology — it requires treating nutritional status as a vital sign in cirrhosis, not an afterthought.

This article is written for general health education. It is not a substitute for individual medical assessment. If you or a family member has cirrhosis and are concerned about muscle loss or nutrition, please consult a qualified hepatologist.